Clinical Trial Update: Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of Taclonex Ointment in adolescents (12-17) with psoriasis vulgaris; results were posted in January 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• Taclonex Ointment (calcipotriene and betamethasone dipropionate)

Snippet

Sponsor: LEO Pharma | Conditions: Psoriasis Vulgaris | Phase 2 | Status: COMPLETED | Results posted: 2013-01-07